跳至主要内容
临床试验/NCT06751056
NCT06751056招募中不适用

Neck Traction to Reduce Gabaergic Medication Use for Neuropathic Itch- A Pilot Study

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2025年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
Mayo Clinic
入组人数
12
试验地点
2
主要终点
Change in GABAergic medication usage

研究概览

简要总结

The purpose of this study is to determine if cervical traction is an effective treatment to reduce GABAergic medication use for scalp, arm, and upper back neuropathic itch.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Persons with scalp, arm, and upper back pruritus without primary skin lesions.
  • Persons 18 or older.
  • Person on a stable dosage of gabapentin or pregabalin over the preceding 4 week period.
  • Persons willing and able to comply with clinic visits and study-related procedures.
  • Persons willing and able to understand and complete study-related questionnaires.
  • Persons willing and able to provide voluntary signed informed consent.

排除标准

  • Primary skin lesions driving scalp, arm, or upper back pruritus.
  • A history of spinal surgery or other conditions (acute or traumatic spinal injury, spinal instability, spinal fracture, rheumatoid arthritis, metastatic disease to the spine, spinal cord compression, active infections of the head and neck) that would make neck traction contraindicated.
  • Unable to comfortably lay down on the floor and get back up without assistance.
  • Medical conditions in which gabapentin and/or pregabalin is contraindicated.
  • Current enrollment in physical therapy with exercises addressing the cervical spine.
  • Planned or anticipated use of any prohibited medications or procedures during study treatment.
  • Presence of skin comorbidities that may interfere with study assessments.
  • Currently pregnant or breastfeeding or plans to become pregnant or breastfeed during the participation in the study. Persons of childbearing age who are not on reliable contraception will be considered on a case-by-case basis.
  • o Participants of childbearing age who are not on reliable contraception (hormonal contraceptive pills, patch, or ring, intrauterine device, subdermal hormonal implant, tubal ligation, depot medroxyprogesterone injections) will be required to complete monthly urine pregnancy tests.
  • Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study. Examples include, but are not limited to, a short life expectancy, persons with uncontrolled diabetes (HbA1c ≥ 9%), cardiovascular conditions (e.g. stage III or IV cardiac failure), severe renal conditions (e.g. patients on dialysis), debilitating neurological conditions (e.g. demyelinating diseases), active major autoimmune diseases (e.g. lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), or other severe endocrinological, gastrointestinal, hepatobiliary, metabolic, pulmonary, or lymphatic diseases. The specific justification for persons excluded under this criterion will be noted in study documents.
  • Any other medical or psychological condition (including relevant laboratory abnormalities at screening) that, in the opinion of the investigator, may suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his/her participation in this clinical trial, may make participation unreliable, or may interfere with study assessments. The specific justification for persons excluded under this criterion will be noted in study documents.

研究组 & 干预措施

Cervical Traction Group

Experimental

Patients who are on a stable dosage of gabapentin or pregabalin for scalp, arm or upper back pruritus without primary rash

干预措施: Cervical Traction Device (Device)

结局指标

主要结局

Change in GABAergic medication usage

时间窗: Baseline, 12 weeks

Reported as percentage of reduction in dosage of gabapentin or pregabalin after 12 weeks of home neck traction.

次要结局

  • Pruritus Severity Score(Baseline, 14 days, 28 days, 42 days, 56 days, and 72 days)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

David L. Swanson

Professor of Dermatology

Mayo Clinic

研究点 (2)

Loading locations...

相似试验